News

SUTENT is an oral multi-kinase inhibitor that works by blocking multiple molecular targets implicated in the growth, proliferation and spread of cancer. The FDA approval is based on

The completed integration is expected to enable the rapid transfer of Phase I data and metadata collected in ALPHADAS into Medidata Rave. ALPHADAS is a multi-study, schedule-driven, automated

The CHMP has recommended the marketing authorization of Benlysta as an add-on therapy in adult patients who are suffering from active autoantibody-positive systemic lupus erythematosus, with a high

The data demonstrated statistical prominence in every category analyzed, with only very minor and minimal adverse events. The study involved around 604 intent-to-treat patients. On the basis of

The approval is based on the ADVANCE-2 and ADVANCE-3 clinical trials, part of the EXPANSE clinical trial program. ELIQUIS is an oral anticoagulant with a 12- to 24-hour

PinAAcle series’ configuration allows for compact design in applications like environmental regulations for drinking water, clinical usage in customer-validated applications such as screening for lead, and requirements of

The latest facility is one of a network of six global RD&I centers that work with the company’s businesses . The six global RD&I centers host a combination

The CHMP’s opinion was for the combination of Victrelis with peginterferon alfa and ribavirin, in adult patients with compensated liver disease who are previously untreated or who have

Xiapex is a new non-surgical injectable treatment option for Dupuytren’s contracture in adult patients with a palpable cord. So far, Pfizer has paid $52.5m of regulatory milestones to